Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce a collaboration with Sartorius Stedim Cellca (Cellca) to evaluate and test its customised synthetic promoters with Sartorius’ proprietary mammalian production cell platform. The goal of the programme is to reduce timelines and increase yields in the development of stable cell lines for the production of biopharmaceuticals.
Edinburgh, UK, 22nd June 2016 / Synpromics Ltd, the leading synthetic promoter company, is pleased to announce an extension to the original collaboration with uniQure announced in January 2015, which focused on the development of synthetic promoters with up-regulated liver cell specific activity suitable for gene expression using an AAV vector.
Synpromics appoints Dr John Shields as Investor Director and Dr Ken Macnamara as Director of Operations.
Synpromics Ltd, a leading synthetic biology company, and The Cell Therapy Catapult announce the launch of a collaboration to remove a major barrier to the development of the cell and gene therapy.
Synthetic promoters to be developed for gene therapy in eye disease.